Search research articles
Contact Us
Filters
Showing results (151-160 of 202) with videos related to
Page
of 21
Sort By:
Ebiomedicine
|
February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial
Maurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
JAMA Network Open
|
September 15, 2025
Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024
Ariana P Toepfer, Rachel E Rutkowski, Leila C Sahni, et al.
Frontiers in Immunology
|
May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Cassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Pediatrics
|
January 19, 2019
Factors Associated With Rotavirus Vaccine Coverage
Negar Aliabadi, Mary E Wikswo, Jacqueline E Tate, et al.
The Journal of Pediatrics
|
April 1, 2024
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019
Benjamin R Clopper, Yingtao Zhou, Ayzsa Tannis, et al.
Virus Evolution
|
September 15, 2021
Comparative genomic analysis of genogroup 1 and genogroup 2 rotaviruses circulating in seven US cities, 2014-2016
Mathew D Esona, Rashi Gautam, Eric Katz, et al.
Plos Medicine
|
November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
MMWR. Morbidity and Mortality Weekly Report
|
November 30, 2023
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Ayzsa Tannis, Janet A Englund, Ariana Perez, et al.
JAMA Network Open
|
June 2, 2025
Neurologic and Psychological Outcomes 2 Years After Multisystem Inflammatory Syndrome in Children
Caitlin K Rollins, David Wypij, Laura D Zambrano, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 202) with videos related to
Sort By:
Page
of 21
Ebiomedicine
|
February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial
Maurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
JAMA Network Open
|
September 15, 2025
Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024
Ariana P Toepfer, Rachel E Rutkowski, Leila C Sahni, et al.
Frontiers in Immunology
|
May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Cassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Pediatrics
|
January 19, 2019
Factors Associated With Rotavirus Vaccine Coverage
Negar Aliabadi, Mary E Wikswo, Jacqueline E Tate, et al.
The Journal of Pediatrics
|
April 1, 2024
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019
Benjamin R Clopper, Yingtao Zhou, Ayzsa Tannis, et al.
Virus Evolution
|
September 15, 2021
Comparative genomic analysis of genogroup 1 and genogroup 2 rotaviruses circulating in seven US cities, 2014-2016
Mathew D Esona, Rashi Gautam, Eric Katz, et al.
Plos Medicine
|
November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
MMWR. Morbidity and Mortality Weekly Report
|
November 30, 2023
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Ayzsa Tannis, Janet A Englund, Ariana Perez, et al.
JAMA Network Open
|
June 2, 2025
Neurologic and Psychological Outcomes 2 Years After Multisystem Inflammatory Syndrome in Children
Caitlin K Rollins, David Wypij, Laura D Zambrano, et al.
Page
of 21